Miracell to Target the Middle East with ‘Smart M-Cell 2’ Following Europe
Participating in Dubai International Medical Device Exhibition
Following its success in the European market, stem cell specialist Miracell (CEO Shin Hyun-soon) is targeting the Arab market.
Miracell announced on the 19th that it will participate in the “Dubai International Medical Device Exhibition (Arab Health 2022)” held in Dubai from the 24th to the 27th.
The Dubai International Medical Device Exhibition, held in 1976 and now in its 47th year, is the largest medical device exhibition in the Middle East and one of the world’s four largest medical device exhibitions. Last year, it attracted 110,000 attendees from 64 countries.
Miracell will showcase its “Smart M-Cell 2,” a “state-of-the-art bio-stem cell extraction system” developed using domestic technology.
Furthermore, through membership in the Cellpia Global Platform (CGP), the company has built an organic network with doctors and medical staff at hospitals and clinics both domestically and internationally, sharing specialized stem cell medical technology. CGP provides education, technology transfer, medical system setup, and marketing for safe stem cell regenerative medicine treatments at hospitals both domestically and internationally.
CEO Shin Hyun-soon stated, “At an exhibition held in Germany, Miracell secured contracts from buyers who expressed satisfaction with Miracell’s bio-stem cell system, which received European CE certification, and its therapeutic effects for psoriasis and other conditions.” He added, “We will continue our success in Europe in the Middle East and expand globally.”
He added, “We are currently pursuing global patents, including those from the FDA, in over 40 countries, so our future sales outlook is bright.”